Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial

This cohort study examines whether consumption of a high-cannabidiol product resulted in detectable amounts of Δ9-tetrahydrocannabinol metabolites in the urine samples of participants.

Detalles Bibliográficos
Autores principales: Dahlgren, M. Kathryn, Sagar, Kelly A., Lambros, Ashley M., Smith, Rosemary T., Gruber, Staci A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429743/
https://www.ncbi.nlm.nih.gov/pubmed/33146684
http://dx.doi.org/10.1001/jamapsychiatry.2020.3567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429743/
https://www.ncbi.nlm.nih.gov/pubmed/33146684
http://dx.doi.org/10.1001/jamapsychiatry.2020.3567

Ejemplares similares